Tissue Therapies Limited is an Australian biomedical company listed on the Australian Stock Exchange developing biomedical technologies for wound healing, tissue repair and cell culture applications.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology.

The Company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited’s shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

What is VitroGro® ECM and how does it help?

VitroGro® ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.

When applied, it replaces a dysfunctional wound matrix by forming a scaffold that helps restore the wound healing process.

Hard to heal wounds are associated with a damaged extracellular matrix (ECM). A functional ECM is required for normal healing to proceed. VitroGro® ECM is an ECM replacement that improves wound care and healing.

VitroGro® ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration.

VitroGro® ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.

VitroGro® ECM is intended for the treatment of hard to heal wounds, primarily venous ulcers, and may be used in conjunction with standard wound care including compression bandaging.

VitroGro® ECM facilitates wound closure and may improve wound care by reducing pain.

Wound Healing

Tissue Therapies Limited has identified that there is a significant need in wound care for improving the outcome of hard to heal wounds. Hard to heal wounds are defined as wounds that have not responded to standard therapy in an orderly and timely manner.

This type of delayed healing occurs in a variety of wound types (venous leg ulcers, arterial leg ulcers, mixed leg ulcers, diabetic foot ulcers and pressure ulcers).

*Treatment once per week for an average of 8-10 weeks is required for complete healing
**VitroGro® ECM: summary of clinical results**

A multi-centre clinical trial was conducted to establish the safety and effectiveness of VitroGro® ECM.

This trial involved patients with hard to heal leg ulcers (venous and mixed) up to 33 cm² in size at baseline.

The patients who completed the trial had at baseline a mean ulcer duration of 37.1 months, a mean age of 74.2 years, and a mean ulcer area of 7.4 cm².

VitroGro® ECM was applied for 12 weeks, or until healed (whichever came first), in conjunction with standard care, including compression therapy.

Wound area reduction greater than 50% was achieved in 64.4% (29 patients), a wound area reduction greater than 90% was attained in 42% (19 patients) and complete healing was observed in 35.6% (16 patients).

**Dermal Substitutes for Chronic Wounds**

To successfully break the cycle of chronicity, scaffolds need to be appropriate for early wound healing as this is the key to consistent healing. Preferably they should not be animal derived. They must also be easy to use (topical treatments) and cost effective for employment in a clinical setting.

**Target Product Applications**

**Diabetic, Venous & Pressure Ulcer treatments**

- Improved healing (1 application per week)
- Correction of wound healing pathology

**Burns Dressing: Paediatric & Adult**

- Accelerated scarless healing

**Surgical Wound Applications**

- Would closure for at-risk patients, eg obese, diabetic, smoker, advanced vascular disease
- Other applications, eg stoma care

**Product Cascade - Specialist Unit to Retail**

- Specialist Unit - general hospital, outpatient, GP, pharmacy, retail
- Potential retail applications include dressings, creams, lotions, product range for burns, chronic wounds, acute sunburn etc.

**Investment Opportunity**

- Currently seeking Middle East Distribution Partner
- Currently seeking Cornerstone investor(s) / JV specific interest

---

**Disclaimers**

- Montpellier Corporate Advisory (assumes financial data, which is all obtained from client companies, to be correct and carries no responsibility for ensuring the accuracy or validity of that data.
- Montpellier reviews the financial data to ensure that basic criteria are met, such as arithmetic validation and examining financial data items for large variances. Where these tests fail, client companies are requested to make the necessary corrections to the data and the data is rechecked. Montpellier does not change any figures reported by the client companies.
- In some cases, where Montpellier has calculated equity cash flows, valuations, returns and other statistics based on financial data obtained from client companies, Montpellier makes all reasonable efforts to ensure the validity of calculations presented in the reports, but minor errors are possible.
- Montpellier will endeavour to provide the most complete and relevant information possible and may from time to time make changes to the reports.
- Montpellier has discretion on the choice of charts, cash flows, valuations, returns and other statistics presented in the reports.
- The information provided by Montpellier should not be considered an investment recommendation. Montpellier carries no liability for any investment decision based on reported data.

**Disclosure**

Montpellier has been mandated in most cases by each of their client companies to facilitate the introduction of parties who may wish to provide equity and/or debt finance for the projects/purposes listed. Montpellier is an Australian registered company whose main source of revenue is from client investee companies, either through a retainer and/or success fee for introduction of parties who subsequently decide to participate in equity and/or debt financing in the investee company. Potential investor parties should therefore seek their own independent advice in relation to the opportunities presented by Montpellier. If an investor requires more detailed information about an opportunity, a confidentiality and non-circumvention agreement must be signed and all enquiries routed through Montpellier in the first instance.

For further information please contact Mohamed Mughal:

Mobile: +971 50 473 2524 or Email: mmughal@montpelliercorp.com